Rifampicin and isoniazid drug resistance among patients diagnosed with pulmonary tuberculosis in southwestern Uganda.
Rifampicin and isoniazid drug resistance among patients diagnosed with pulmonary tuberculosis in southwestern Uganda.
复制标题
DOI：
10.1371/journal.pone.0259221
复制
发表时间：
2021
期刊：
影响因子：
3.7
通讯作者：
Bazira J
中科院分区：
文献类型：
--
作者：
Micheni LN;Kassaza K;Kinyi H;Ntulume I;Bazira J
耐多药结核病（MDR-TB）已成为全球结核病控制的主要威胁。乌干达是结核病发病率较高的国家之一，尽管作出了重大控制努力。在这项研究中，结核分枝杆菌对利福平（RIF）和异烟肼（INH）的耐药性进行了调查，在乌干达西南部诊断为肺结核患者。2018年5月至2019年4月期间，在四个不同的结核病诊断中心收集了283份痰液样本（266份来自新诊断患者，17份来自既往治疗患者），使用高分辨率熔解曲线分析评估了RIF和INH耐药性。INH和RIF单药耐药率分别为8.5%和11%，MDR-TB为6.7%。双变量分析显示，年龄在25 ~ 44岁的患者发生耐多药结核病的风险较高（cOR 0.253）。新诊断患者中INH、RIF和MDR-TB单耐药率分别为8.6%、10.2%和6.4%，而既往治疗患者中INH、RIF和MDR-TB单耐药率分别为5.9%、23.5%和11.8%。这些比率高于先前报告的比率，表明结核分枝杆菌耐药性上升，可能需要采取措施防止耐药性进一步上升。还需要经常进行耐药性调查，以监测和遏制耐药性结核病的发展和蔓延。
Multidrug-resistant tuberculosis (MDR-TB) has become a major threat to the control of tuberculosis globally. Uganda is among the countries with a relatively high prevalence of tuberculosis despite significant control efforts. In this study, the drug resistance of Mycobacterium tuberculosis to rifampicin (RIF) and isoniazid (INH) was investigated among patients diagnosed with pulmonary tuberculosis in Southwestern Uganda. A total of 283 sputum samples (266 from newly diagnosed and 17 from previously treated patients), collected between May 2018 and April 2019 at four different TB diagnostic centres, were assessed for RIF and INH resistance using high-resolution melt curve analysis. The overall prevalence of monoresistance to INH and RIF was 8.5% and 11% respectively, while the prevalence of MDR-TB was 6.7%. Bivariate analysis showed that patients aged 25 to 44 years were at a higher risk of developing MDR-TB (cOR 0.253). Furthermore, among the newly diagnosed patients, the prevalence of monoresistance to INH, RIF and MDR-TB was 8.6%, 10.2% and 6.4% respectively; while among the previously treated cases, these prevalence rates were 5.9%, 23.5% and 11.8%. These rates are higher than those reported previously indicating a rise in MTB drug resistance and may call for measures used to prevent a further rise in drug resistance. There is also a need to conduct frequent drug resistance surveys, to monitor and curtail the development and spread of drug-resistant TB.
登录
查看更多内容
影响因子：
3.7
作者：
Kigozi E;Kasule GW;Musisi K;Lukoye D;Kyobe S;Katabazi FA;Wampande EM;Joloba ML;Kateete DP
通讯作者：
Kateete DP
影响因子：
9.4
作者：
Ramirez, Melissa V.;Cowart, Kelley C.;Posey, James E.
通讯作者：
Posey, James E.
影响因子：
11.8
作者：
Nachega, JB;Chaisson, RE
通讯作者：
Chaisson, RE
影响因子：
3.7
作者：
Lukoye, Deus;Adatu, Francis;Joloba, Moses L.
通讯作者：
Joloba, Moses L.
影响因子：
3.7
作者：
Okethwangu, Denis;Birungi, Doreen;Zhu, Bao-Ping
通讯作者：
Zhu, Bao-Ping